Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5673
Source ID: NCT00736515
Associated Drug: Gliclazide Mr And Insulin Glargine Injection
Title: Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
Acronym: CODMS
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: Gliclazide MR and Insulin Glargine Injection|DRUG: Biosynthetic Human Insulin Injection
Outcome Measures: Primary: Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG, 3 months | Secondary: MBG, SDBG, MAGE and MODD in the 48th CGMS, 3 months|Incidence of hypoglycemia and severe hypoglycemia, 3 months|Weight change, 3 months
Sponsor/Collaborators: Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 160
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2008-10
Completion Date: 2011-08
Results First Posted:
Last Update Posted: 2020-04-03
Locations: Peking University First Hospital, Beijing, Beijing, 100034, China|Beijing Hospital, Beijing, Beijing, 100730, China|Guangdong General Hospital, Guangzhou, Guangdong, 510080, China|The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086, China|Tongji Hospital of Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, 430030, China|Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 200233, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|SIR RUN RUN SHAW Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310016, China
URL: https://clinicaltrials.gov/show/NCT00736515

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D333 Gliclazide small molecule DB01120 Details